title: Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients.
abstract: The Escherichia Coli bacterial extract (OM-89) is used in the treatment of rheumatoid arthritis (RA). We evaluated the immunological changes induced by oral administration of OM-89 in 12 RA patients (polyclonal T cell reactivity to PHA, T cell precursor frequencies specific for OM-89 and Tetanus toxoid (TT), a control antigen and the release of Th1 (IFN-gamma, TNF-alpha), Th2 (IL-4) and T regulatory 1 cell (Tr1) (IL-10) cytokines in the supernatants of PBMC cultures. Stimulation index in response to PHA decreased at month 3 as well as T cell precursor frequencies specific for TT with similar trends for OM-89-specific T cell precursor frequencies. OM-89 induced a strong production of IL-10, a significant decrease in IL-4 production while TNF-alpha and IFN-gamma production tended to decrease during the study. Our results suggest that OM-89 has immunomodulatory properties by inducing changes in PBMC cytokines release suggestive of an induced Tr1 response to OM-89.
authors.affiliation: Department of Rheumatology, University Hospital Jean Minjoz, Bd Fleming, F-25030 Besançon cédex, France. eric.toussirot@ufc-chu.univ-fcomte.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Toussirot
authors.forename: Eric
authors.initials: E
authors.lastname: Robinet
authors.forename: Philippe
authors.initials: P
authors.lastname: Saas
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Chabod
authors.forename: Benoît
authors.initials: B
authors.lastname: Augé
authors.forename: Gabriel
authors.initials: G
authors.lastname: Cozma
authors.forename: Pierre
authors.initials: P
authors.lastname: Tiberghien
authors.forename: Jean
authors.initials: J
authors.lastname: Roudier
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
mesh_terms: D000368:Aged; D000942:Antigens, Bacterial / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D000942:Antigens, Bacterial; D007155:Immunologic Factors; D010835:Phytohemagglutinins; D014409:Tumor Necrosis Factor-alpha; C050501:OM 89; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma